# Effect of Pembrolizumab (Keytruda®) on Biomarkers in Early Breast Cancer.

> **NCT03197389** · EARLY_PHASE1 · COMPLETED · sponsor: **Universitaire Ziekenhuizen KU Leuven** · enrollment: 54 (actual)

## Conditions studied

- Breast Cancer
- Triple Negative Breast Cancer
- Hormone Receptor Negative Neoplasm

## Interventions

- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03197389
- **Lead sponsor:** Universitaire Ziekenhuizen KU Leuven
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-18
- **Primary completion:** 2020-03-31
- **Final completion:** 2020-03-31
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2021-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03197389

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03197389, "Effect of Pembrolizumab (Keytruda®) on Biomarkers in Early Breast Cancer.". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03197389. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*